A case of primary Epstein‐Barr virus‐associated cutaneous diffuse large B‐cell lymphoma unassociated with iatrogenic or endogenous immune dysregulation

Tokuda, Yasutaka; Fukushima, Mana; Nakazawa, Koh; Oguchi, Shinji; Koganehira, Yoko; Yamaura, Maki; Iijima, Masayoshi; Murata, Hiroshi; Uhara, Hisashi; Takata, Minoru; Saida, Toshiaki; Katsuyama, Tsutomu; Nakamura, Shunya

doi:10.1111/j.1600-0560.2007.00859.x

Cited by 19 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study showed that none of the patients were positive for EBV. Although, there are handful of case reports 12,13 suggesting EBV positivity in PCLBCL, interpretation of case reports need to done carefully. Furthermore, it is important to underscore that the role of EBV in DLBCL may be limited.…”

Section: Discussionmentioning

confidence: 95%

Primary Cutaneous Large B-Cell Lymphoma Shows Activation of Nuclear Factor Kappa B and Low Incidence of Epstein-Barr Virus

Bhagavathi¹,

Blenc²,

Amin³

et al. 2010

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Primary cutaneous lymphomas are defined as lymphomas, which are present in the skin without evidence of extracutaneous disease at the time of diagnosis. Primary cutaneous large B-cell lymphoma (PCLBCL) is a subtype of primary cutaneous B-cell lymphoma with a female predominance, occurring in elderly patients and known to have unfavorable prognosis. We evaluated 10 cases of PCLBCL in immunocompetent patients between 2005 and 2008. A panel of immunoperoxidase stains; CD3, CD10, CD20, BCL2, BCL6, and MUM1 were performed on all cases. Nuclear factor kappa B (NF-kappaB) pathway activation was evaluated using an immunostain for P65. The presence of Epstein-Barr virus (EBV) was assessed using Epstein-Barr virus encoded RNA (EBER) in situ hybridization probe. All cases were CD20 positive and CD3 negative. CD10, BCL6, BCL2, and MUM1 were positive in 4/10 (40%), 6/10 (60%), 7/10 (70%), and 7/10 (70%) cases, respectively. NF-kappaB activation was detected in 7/10 (70%) cases. One (10%) case was positive for EBV by in situ hybridization. Interestingly, the EBV positive case was also positive for MUM1 and negative for CD10, indicating an activated immunophenotype. In conclusion, majority of PCLBCL shows activation of NF-kappaB pathway with a low incidence of EBV.

show abstract

Section: Discussionmentioning

confidence: 95%

Primary Cutaneous Large B-Cell Lymphoma Shows Activation of Nuclear Factor Kappa B and Low Incidence of Epstein-Barr Virus

Bhagavathi¹,

Blenc²,

Amin³

et al. 2010

The American Journal of Dermatopathology

View full text Add to dashboard Cite

show abstract

“…Primary cutaneous EBV‐positive DLBCL, NOS is extremely rare and always effects elderly patients . This condition should be distinguished from EBV‐positive mucocutaneous ulcers; secondary cutaneous EBV‐positive DLBCL, NOS; and primary cutaneous EBV‐positive DLBCL with immunocompromise.…”

Section: Discussionmentioning

confidence: 99%

Primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report

Zhou

2019

J Cutan Pathol

View full text Add to dashboard Cite

Primary cutaneous EBV (Epstein‐Barr virus)‐positive diffuse large B‐cell lymphoma, not otherwise specified (DLBCL, NOS), is an extremely rare disease. The clinical and pathological features of DLBCL, NOS have not been clearly illustrated. We report a case of primary cutaneous EBV‐positive DLBCL, NOS in a 35‐year‐old Chinese male with multiple ulcerated and nodular lesions on his trunk and arms for 6 months. No other organs, except the skin, were involved. The lesions were localized in the dermis with focal necrosis. The tumor cells were immunoblastic‐ or centroblastic‐like cells and diffusely distributed. There were numerous inflammatory cells in the background. The tumor cells were positive for CD20, PAX‐5, MUM1, LMP1, CD30, and Epstein‐Barr virus encodedsmall RNA, but negative for EBNA2. Polymerase chain reaction showed a monoclonal IG gene rearrangement. The patient received 6 cycles of CHOP (cyclophosphamide, hydroxydaunorubicin, Oncovin®, prednisone) chemotherapy and went into complete remission. There was no evidence of relapse after 35 months of follow‐up.

show abstract

“…[308][309][310][311][312] It is thought that the pathogeneses of these lymphomas are related with the compromise of the cellular immunity inherent to old age. 316,317 Two main morphologic subtypes are recognized: a polymorphous subtype and a large cell lymphoma subtype. 316,317 Two main morphologic subtypes are recognized: a polymorphous subtype and a large cell lymphoma subtype.…”

Section: Diffuse Large B-cell Lymphoma In Elderly Patientsmentioning

confidence: 99%

“…310 Even so, the task is not always easy because about 10%-20% of HL express CD20. 316,317 Necrosis and an angiocentric pattern are not uncommon.…”

Section: Diffuse Large B-cell Lymphoma In Elderly Patientsmentioning

confidence: 99%

Epstein–Barr Virus in Cutaneous Pathology

Fernández-Flores

2013

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is a ubiquitous double-stranded DNA gamma herpes virus and it is present in 95% of adults. EBV infection is seen in many oncological conditions, although there is controversy regarding whether EBV is causative, a cofactor, or just a coincidental infection. Some of these conditions involve the skin as the main or as a secondary organ. In this report, we review several tumoral and nontumoral cutaneous conditions, which are related to EBV infection, and describe the epidemiology of infection and the life cycle of the virus.

show abstract

A case of primary Epstein‐Barr virus‐associated cutaneous diffuse large B‐cell lymphoma unassociated with iatrogenic or endogenous immune dysregulation

Cited by 19 publications

References 17 publications

Primary Cutaneous Large B-Cell Lymphoma Shows Activation of Nuclear Factor Kappa B and Low Incidence of Epstein-Barr Virus

Primary Cutaneous Large B-Cell Lymphoma Shows Activation of Nuclear Factor Kappa B and Low Incidence of Epstein-Barr Virus

Primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report

Epstein–Barr Virus in Cutaneous Pathology

Contact Info

Product

Resources

About